LY2951742 Biomarker Study in Patients With Migraine
Phase of Trial: Phase 0
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Biomarker; Pharmacodynamics
- Sponsors Eli Lilly
- 25 Jan 2017 Status changed from recruiting to completed.
- 10 Oct 2016 Status changed from not yet recruiting to recruiting.
- 09 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.